

## AMENDMENT

### Listing of Claims

Please amend the claims as follows:

1. (Currently Amended) A method for purifying cancer-specific Proliferating Cell Nuclear Antigen (csPCNA) comprising the steps of:
  - (A) obtaining a tissue or body fluid sample comprising csPCNA;
  - (B) contacting said sample with a peptide comprising the amino acid sequence  
LeuLysGlnLeuAspAlaGlnGlnThrGlnLeuArgIleAspSerPhePheArgLeu  
AlaGlnGlnGluLysGluAspAlaLysArg (SEQ ID No:1),  
wherein said peptide is immobilized on a solid support and binds to said csPCNA to form a peptide-csPCNA complex; and
  - (C) isolating csPCNA from said peptide-csPCNA complex so as to purify said csPCNA.
  
2. (Original) The method of Claim 1, wherein prior to step (B) the thus obtained tissue or body fluid sample of step (A) is subjected to a process comprising:
  - (1) homogenizing cells constituting said tissue or body fluid to obtain a homogenate (H);
  - (2) separating said H into a nuclear pellet fraction (NP) and a cytosolic fraction (S1);
  - (3) extracting nuclei from said NP to obtain a nuclear extract (NE);
  - (4) subjecting said S1 to centrifugation to obtain a post-mitochondrial cytosolic supernatant (S2);
  - (5) subjecting said S2 to centrifugation to obtain a post-mitochondrial/post-microsomal cytosolic supernatant (S3);
  - (6) combining said NE and said S3 to form an NE/S3 fraction, applying the resulting NE/S3 fraction to a weak anion exchange matrix column and collecting the flow through (PCFT);

- (7) applying the resulting PCFT to a hydrophobic chromatography matrix column, eluting the column with buffer comprising ethylene glycol and collecting the eluant (PSE);
    - (8) dialyzing out ethylene glycol present in the PSE to obtain a dialyzate; and
    - (9) applying the resulting dialyzate to a strong anion exchange matrix column, eluting with a dialyzate buffer comprising a salt gradient, and collecting and pooling PCNA-containing fractions to obtain said sample.
3. (Previously Presented) The method of Claim 1 or 2, wherein said tissue or body fluid sample of step (A) further comprises native PCNA (nPCNA), said nPCNA does not bind to said peptide in step (B), whereas said csPCNA binds to said peptide in step (B) to form a peptide-csPCNA complex and in step (C) isolating csPCNA is effected using an elution buffer whereby csPCNA is eluted from said csPCNA-complex.
4. (Original) An immunoassay for detecting csPCNA comprising:
  - (1) contacting a test sample with a peptide comprising the amino acid sequence  
LeuLysGlnLeuAspAlaGlnGlnThrGlnLeuArgIleAspSerPheP  
heArgLeuAlaGlnGlnGluLysGluAspAlaLysArg (SEQ ID  
No:1), which has been immobilized on a solid support so as  
to bind csPCNA to said peptide to form a peptide-csPCNA  
complex; and
  - (2) contacting said peptide-csPCNA complex with an anti-PCNA antibody and detecting binding of said antibody to said complex.
5. (Original) The immunoassay of Claim 4, wherein said assay is an ELISA and

said antibody is labeled with a detectable enzyme.

6. (Original) The immunoassay of Claim 5, wherein said enzyme is horse radish peroxidase.
7. (Original) The immunoassay of Claim 5, wherein said peptide is a fusion protein comprising said peptide and Glutathione-S-Transferase.
8. (Previously Presented) The immunoassay of Claim 7, wherein said fusion protein is biotinylated and immobilized on said solid support via streptavidin-coated on said solid support.
9. (Currently Amended) The method of Claim 1, wherein the tissue or body fluid sample obtained is afflicted with a cancer selected from the group consisting of carcinomas, sarcomas, lymphomas, [[or]] and leukemias.
10. (Currently Amended) The method of Claim 9, wherein the tissue or body fluid sample obtained is selected from the group consisting of cervical, mammary glands, esophageal, glial cells, lung, stomach, intestine, prostate, white blood cells, urine, serum, [[or]] and whole blood.
11. (Currently Amended) The method of Claim 1, wherein said peptide is a fusion protein comprising said peptide and at least one of Glutathione-S-Transferase, Calmodulin Binding protein, [[and]] or oligo (6X) histidine.
12. (Cancelled)
13. (Withdrawn) The method of Claim 3, further comprising the step of identifying the site(s) on the PCNA polypeptide that is (are) modified in nPCNA and lacking from csPCNA.

14. (Withdrawn) The method of Claim 13, further comprising the step of identifying the metabolic pathways that mediate the addition or removal of this (these) post-translation modifications.
15. (Withdrawn) The method of Claim 1, further comprising the step of developing specific inhibitors for csPCNA.
16. (Currently Amended) The immunoassay of Claim 4, wherein the test sample is afflicted with a cancer selected from the group consisting of carcinomaomas, sarcomas, lymphomas, [[or]] and leukemias.
17. (Currently Amended) The immunoassay of Claim 16, wherein the test sample is obtained by selecting from the group consisting of cervical, mammary glands, esophageal, glial cells, lung, stomach, intestine, prostate, white blood cells, urine, serum, [[or]] and whole blood.
18. (Currently Amended) The immunoassay of Claim 4, wherein said immunoassay is selected from the group consisting of radio-immunoassay, dot blot assay, slot blot assay, immunoprecipitation, protein quantification, imunno-PCR, [[or]] and Western blot.
19. (New) The method of Claim 1, further comprising the step of producing antibodies (monoclonal or polyclonal) specific for csPCNA from said isolated and purified csPCNA.